AI Article Synopsis
- Endomyocardiofibrosis is a type of restrictive cardiomyopathy marked by fibrous tissue affecting the heart's inner lining and nearby muscle, leading to poor ventricular filling while keeping the heart's pumping ability intact.
- Symptoms typically resemble heart failure, emphasizing the need for careful clinical examination to correctly identify the underlying cause.
- The text presents a case of a patient who has biventricular endomyocardial fibrosis linked with renal amyloidosis, illustrating the complexity of diagnosing these conditions.
Article Abstract
Endomyocardiofibrosis is a restrictive cardiomyopathy characterized by fibrotic involvement of the endocardium and adjacent myocardium, and by diastolic dysfunction caused by changes in distensibility making ventricular filling inadequate while preserving the systolic function. Clinically, it appears as heart failure, but etiological symptomatic discernment, suspicion and a clinical examination would be necessary in order to make a correct etiological diagnosis. The case of a patient with biventricular endomyocardial fibrosis associated with renal amyloidosis is presented.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0066-782x2005001700008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MELANOMAS, SARCOMAS, AND RENAL METASTASES IN THE LIVER: HOW TO TREAT?
Arq Bras Cir Dig
January 2025
D'Or Institute for Research and Education, Digestive Surgery Residency Program - Rio de Janeiro (RJ), Brazil.
Liver metastases from melanomas, sarcomas, and renal tumors are less frequent. Treatment and prognosis will depend on whether they are isolated or multiple, size and location, the presence or absence of extrahepatic neoplastic disease, age, stage of the initial disease, initial treatments instituted, time of evolution, and clinical condition of the patient. Recently, a high number of oncological therapies including monotherapy or in combination, neoadjuvants or adjuvants, and immuno-oncological treatments have been developed and tested, increasing disease-free time and survival.
View Article and Find Full Text PDFThe relationship between insulin resistance and fibroblast growth factor 23 in patients with non-diabetic pre-dialysis chronic kidney disease: a cross-sectional study.
Sao Paulo Med J
January 2025
Associate Professor, Department of Nephrology, Ankara Bilkent City Hospital, Ankara, Turkey.
Background: Insulin resistance often occurs in patients with chronic kidney disease (CKD) owing to mineral and bone metabolism disorders. Fibroblast growth factor (FGF)-23 and soluble klotho (s-KL) play crucial roles in linking CKD with mineral and bone metabolism.
Objective: This study aimed to examine the relationship between insulin resistance and FGF-23 and s-KL in patients with non-diabetic pre-dialysis patients with CKD.
[Association between occupational exposure to pesticides and ototoxicity in farmers of Pontal do Paranapanema-SP, Brazil].
Cien Saude Colet
January 2025
Departamento de Química, Universidade do Oeste Paulista. São Paulo SP Brasil.
The scope of this study was to assess the ototoxic effects and general health of farmers exposed to pesticides in the Pontal do Paranapanema region, SP, Brazil. Participants of both sexes aged 18-40, 40-60 and >60 years were allocated into two groups: Non-Exposed Group (NEG) and Occupationally Exposed Group (OEG). A questionnaire of exposure and health, meatoscopy, pure tone audiometry, logoaudiometry and immittanciometry were assessed.
View Article and Find Full Text PDF[Analysis of the performance of dialysis centers in referring and enrolling patients into the pre-kidney transplant waiting list in Minas Gerais State, Brazil, 2015 to 2019].
Cad Saude Publica
January 2025
Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brasil.
Despite the relevance of kidney transplantation, the supply of organs and the process for inclusion in its waiting list still represent obstacles. This study aimed to analyze the performance of dialysis centers in referring patients for pre-kidney transplant evaluation and inclusion in the waiting list of incident dialysis patients from 2015 to 2019 in the state of Minas Gerais, Brazil. This retrospective cohort study sampled 23,297 records of patients who underwent dialysis therapy in public or philanthropic institutions or who had their treatment funded by the Brazilian Unified National Health System in private clinics.
View Article and Find Full Text PDFPhase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
January 2025
Roswell Park Cancer Institute, Buffalo, NY, United States.
Background: Data in clear cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of HIF1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.
Patients And Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!